Physician profile
Arvind Kumar Garg
NPI 1154551968
$8,549.67
in general payments reported to CMS, 2019-2025
14 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $4,136 · 2023: $3,631 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,631 · Food and Beverage: $343 · Education: $1.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,630.64 |
| Food and Beverage | $342.60 |
| Education | $1.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $4,199.10 | 2019-2025 | Jynarque |
| Outset Medical INC | $3,630.64 | 2023 | |
| Alexion Pharmaceuticals, INC. | $257.05 | 2019-2025 | Ultomiris |
| Amgen INC. | $154.65 | 2020-2025 | Krystexxa, Tavneos |
| Nxstage Medical, INC. | $73.08 | 2019 | |
| Ardelyx, INC. | $55.43 | 2025 | Ibsrela |
| Novo Nordisk INC | $41.19 | 2025 | Ozempic |
| Mallinckrodt Hospital Products INC. | $28.88 | 2025 | Acthar |
| Akebia Therapeutics INC | $27.84 | 2025 | Vafseo |
| Calliditas Therapeutics US INC. | $26.27 | 2025 | Tarpeyo |
| Daiichi Sankyo INC. | $22.20 | 2025 | Injectafer |
| Astrazeneca Pharmaceuticals Lp | $17.69 | 2025 | |
| Baxter Healthcare | $13.99 | 2019 | |
| Travere Therapeutics, INC. | $1.66 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.